Latest Ratios: P/E Ratio 26.9x · EV/EBITDA 17.3x · ROE N/A. (1997–2026 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $126.3B | $107.4B | $86.2B | $72.0B | $50.6B | $47.2B | $31.3B | $24.6B | $23.1B | $29.4B | $33.1B |
| Enterprise Value | $131.0B | $112.0B | $87.9B | $74.8B | $53.2B | $51.2B | $34.5B | $30.0B | $27.7B | $34.6B | $38.8B |
| P/E Ratio → | 26.88 | 22.55 | 26.17 | 23.98 | 14.22 | 42.34 | — | 27.33 | 688.59 | 440.22 | 6.52 |
| P/S Ratio | 0.30 | 0.27 | 0.24 | 0.23 | 0.18 | 0.18 | 0.13 | 0.11 | 0.11 | 0.14 | 0.17 |
| P/B Ratio | — | — | — | — | — | — | 21.66 | 3.67 | 2.39 | 2.56 | 2.62 |
| P/FCF | 18.29 | 19.85 | 16.50 | 19.85 | 11.00 | 12.10 | 8.03 | 6.36 | 6.64 | 7.82 | 7.91 |
| P/OCF | 20.53 | 17.45 | 14.17 | 16.69 | 9.81 | 10.64 | 6.90 | 5.63 | 5.72 | 6.78 | 6.97 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.28 | 0.24 | 0.24 | 0.19 | 0.19 | 0.14 | 0.13 | 0.13 | 0.17 | 0.20 |
| EV / EBITDA | 17.31 | 15.60 | 17.55 | 16.40 | 10.52 | 14.70 | 7.83 | 7.63 | 6.88 | 8.95 | 9.10 |
| EV / EBIT | 20.29 | 17.37 | 19.05 | 18.55 | 10.92 | 24.30 | — | 21.54 | 31.70 | 66.38 | 5.39 |
| EV / FCF | — | 20.71 | 16.82 | 20.62 | 11.57 | 13.13 | 8.83 | 7.76 | 7.96 | 9.20 | 9.28 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 3.6% | 3.6% | 3.5% | 3.9% | 4.3% | 4.8% | 4.9% | 4.9% | 5.0% | 5.0% | 5.4% |
| Operating Margin | 1.6% | 1.6% | 1.2% | 1.3% | 1.6% | 1.0% | 1.5% | 1.3% | 1.4% | 1.4% | 1.7% |
| Net Profit Margin | 1.2% | 1.2% | 0.9% | 1.0% | 1.3% | 0.4% | -1.9% | 0.4% | 0.0% | 0.0% | 2.6% |
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | -111.3% | 11.0% | 0.3% | 0.6% | 45.0% |
| ROA | 6.0% | 6.0% | 4.6% | 4.6% | 5.7% | 1.7% | -7.2% | 1.5% | 0.1% | 0.1% | 8.8% |
| ROIC | 254.1% | 254.1% | 540.6% | 252.3% | 199.7% | 60.1% | 31.6% | 17.1% | 14.9% | 12.5% | 15.3% |
| ROCE | 44.8% | 44.8% | 30.5% | 26.7% | 30.5% | 15.2% | 17.8% | 14.8% | 13.5% | 11.9% | 14.3% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | 6.50 | 1.40 | 0.78 | 0.68 | 0.68 |
| Debt / EBITDA | 1.20 | 1.20 | 1.48 | 1.62 | 1.44 | 2.17 | 2.14 | 2.39 | 1.89 | 2.04 | 2.00 |
| Net Debt / Equity | — | — | — | — | — | — | 2.16 | 0.80 | 0.48 | 0.45 | 0.46 |
| Net Debt / EBITDA | 0.65 | 0.65 | 0.34 | 0.62 | 0.52 | 1.15 | 0.71 | 1.37 | 1.15 | 1.35 | 1.35 |
| Debt / FCF | — | 0.86 | 0.33 | 0.77 | 0.57 | 1.03 | 0.80 | 1.39 | 1.33 | 1.38 | 1.38 |
| Interest Coverage | 26.11 | 26.11 | 18.03 | 16.59 | 19.67 | 11.83 | -22.20 | 5.59 | 3.31 | 1.84 | 23.37 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.85 | 0.85 | 0.90 | 0.92 | 0.92 | 0.95 | 1.03 | 0.99 | 1.02 | 1.01 | 1.04 |
| Quick Ratio | 0.49 | 0.49 | 0.53 | 0.51 | 0.51 | 0.57 | 0.59 | 0.60 | 0.58 | 0.57 | 0.61 |
| Cash Ratio | 0.06 | 0.06 | 0.09 | 0.09 | 0.10 | 0.07 | 0.14 | 0.09 | 0.08 | 0.07 | 0.08 |
| Asset Turnover | — | 4.90 | 4.78 | 4.58 | 4.44 | 4.17 | 3.66 | 3.77 | 3.59 | 3.45 | 3.26 |
| Inventory Turnover | 16.06 | 16.06 | 15.07 | 14.04 | 13.45 | 13.44 | 11.78 | 13.13 | 12.18 | 12.14 | 12.30 |
| Days Sales Outstanding | — | 25.32 | 26.07 | 25.54 | 25.60 | 25.70 | 29.39 | 31.52 | 31.07 | 31.03 | 33.49 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 0.3% | 0.4% | 0.4% | 0.4% | 0.6% | 0.6% | 0.9% | 1.2% | 1.3% | 0.9% | 0.8% |
| Payout Ratio | 8.0% | 8.0% | 10.5% | 10.5% | 8.2% | 24.9% | — | 32.7% | 858.8% | 391.0% | 4.9% |
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 3.7% | 4.4% | 3.8% | 4.2% | 7.0% | 2.4% | — | 3.7% | 0.1% | 0.2% | 15.3% |
| FCF Yield | 5.5% | 5.0% | 6.1% | 5.0% | 9.1% | 8.3% | 12.5% | 15.7% | 15.1% | 12.8% | 12.6% |
| Buyback Yield | 3.8% | 4.4% | 3.6% | 4.2% | 7.2% | 7.5% | 2.4% | 7.9% | 7.1% | 5.8% | 7.0% |
| Total Shareholder Yield | 4.0% | 4.8% | 4.0% | 4.6% | 7.8% | 8.0% | 3.3% | 9.1% | 8.4% | 6.7% | 7.8% |
| Shares Outstanding | — | $124M | $128M | $134M | $142M | $154M | $161M | $182M | $197M | $209M | $223M |
Includes 30+ ratios · 30 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying MCK stock.
McKesson Corporation's current P/E ratio is 26.9x. The historical average is 21.7x. This places it at the 75th percentile of its historical range.
McKesson Corporation's current EV/EBITDA is 17.3x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 12.4x.
Based on historical data, McKesson Corporation is trading at a P/E of 26.9x. This is at the 75th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
McKesson Corporation's current dividend yield is 0.28% with a payout ratio of 8.0%.
McKesson Corporation has 3.6% gross margin and 1.6% operating margin.
McKesson Corporation's Debt/EBITDA ratio is 1.2x, indicating moderate leverage. A ratio below 2x is generally considered financially healthy.
Key Metrics
Top Statement Risk
Thin margin and working capital volatility
Metrics are mathematically derived from official filings.
Premium Multiple Prices in Specialty Growth
At a 27.64 trailing P/E and 17.88 EV/EBITDA, McKesson trades well above Henry Schein's 12.47 EV/EBITDA, and as reported in the supplied peer data the premium appears to reflect expectations of specialty and oncology-driven earnings expansion rather than current margin strength.
The forward P/E of 23.76 compresses the trailing multiple by roughly 14%, which suggests the market expects recent EPS strength to persist into the next twelve months. Relative to Cardinal Health's 37.58 P/E, McKesson screens cheaper, though Cardinal's elevated multiple appears distorted by its near-zero reported net margin of 0.7%. Investors should treat the multiple as a bet on earnings durability given that net margins have oscillated between 0.3% and 1.7% across the last ten quarters.
Razor-Thin Spread Limits Earning Power
Gross margin of 3.6% and operating margin of 1.6% in 2027Q2 leave McKesson with minimal buffer, and the 1.1% net margin shows how sensitive reported earnings remain to non-operating and one-time items.
Operating margin has ranged from 0.8% to 2.3% across the ten quarters, indicating that the distribution spread is stable in direction but narrow in magnitude. The gap between operating and net margin in several quarters may suggest below-the-line items such as legal accruals or interest expense are material relative to core earnings. Operating margin, rather than net margin, appears to be the cleaner read of underlying earning power for this business.
Interest Coverage Tightens Amid Rising Debt
Interest coverage of 6.20x in 2027Q2 sits below the 8.45x of 2027Q1 and well below the 33.84x peak in 2026Q4, and based on reported figures, debt-to-EBITDA has been volatile between 3.52x and 8.45x across the period.
The coverage swings appear driven more by quarterly EBITDA fluctuation than by a steady debt-service trend, which makes the current 6.20x reading an incomplete signal on its own. Negative shareholders' equity renders debt-to-equity uninformative, so EBITDA-based leverage measures are the relevant gauge. Investors should monitor whether coverage holds above roughly 5x through the next two quarters, as a sustained decline would warrant closer scrutiny of refinancing exposure.
Sub-One Current Ratio Relies on Turnover
A current ratio of 0.90 and quick ratio of 0.52 in 2027Q2 indicate current liabilities exceed current assets, and according to recent SEC filings, cash of $6.5B provides only partial coverage of short-term obligations.
A current ratio consistently below 1.0 is characteristic of distributors that fund inventory with supplier credit, so the level alone does not necessarily signal distress. The quick ratio's dependence on inventory conversion, with DIO near 23 days, means liquidity is tied to rapid turnover. Under a severe stress scenario involving supplier term contraction, the thin buffer would be tested quickly, and this dependence warrants monitoring.
Negative Cash Conversion Cycle Funds Operations
A cash conversion cycle of negative 8 days in 2027Q2 and 2027Q1, combined with DPO of 57 days against DIO of 23 days, suggests McKesson relies on supplier financing, and as reported in the quarterly data, asset turnover of 1.23x supports the volume-driven model.
The negative CCC has widened from roughly -3 days in 2025Q3 to -8 days recently, meaning the company appears to be extracting progressively more working capital from suppliers relative to its inventory cycle. This structure may explain much of the cash flow volatility observed elsewhere, since working capital swings can reverse quickly if payment terms normalize. The durability of this advantage depends on continued supplier acceptance of extended terms.
Supplier Financing Could Reverse Quickly
The bull case rests on McKesson's negative cash conversion cycle and recent EPS beat, yet based on reported figures the working capital benefit is the most reversible component of the earnings and cash profile.
If the widening negative CCC reflects temporary favorable payment timing rather than durable terms, a normalization toward neutral working capital would remove a meaningful share of recent operating cash flow. Combined with a 1.6% operating margin, even modest pricing pressure or a 340B-related volume reduction could shift the trajectory quickly. Investors should weigh whether the current forward P/E of 23.76 already discounts a sustained working capital tailwind that may not persist.